Celldex Therapeutics: Peers

The FY2025 (Dec) proxy of Celldex Therapeutics names 24 peer companies for pay. Among Celldex Therapeutics and these peers, CEO pay was 9th highest of 10 and total shareholder return was 4th highest of 10.

9th highest of 10in Celldex Therapeutics and its pay peers, FY2025 (Dec) by CEO pay:

$4.8M$19.2M

4th highest of 10in Celldex Therapeutics and its pay peers, FY2025 (Dec) by total shareholder return:

$15$524

Pay peer group, FY2025 (Dec) proxy

Madrigal Pharmaceuticals
BridgeBio Pharma
Protagonist Therapeutics
ImmunityBio
Cytokinetics
Immunovant
Vir Biotechnology
CRISPR Therapeutics AG
Denali Therapeutics
Apellis PharmaceuticalsNot disclosedNot disclosed
ArcellxNot disclosedNot disclosed
ArvinasNot disclosedNot disclosed
BiohavenNot disclosedNot disclosed
Blueprint MedicinesNot disclosedNot disclosed
InhibrxNot disclosedNot disclosed
Iovance BiotherapeuticsNot disclosedNot disclosed
Keros TherapeuticsNot disclosedNot disclosed
Kiniksa PharmaceuticalsNot disclosedNot disclosed
MorphicNot disclosedNot disclosed
Roivant SciencesNot disclosedNot disclosed
SpringWorks TherapeuticsNot disclosedNot disclosed
Syndax PharmaceuticalsNot disclosedNot disclosed
VaxcyteNot disclosedNot disclosed
Zentalis PharmaceuticalsNot disclosedNot disclosed
24 companies

Changes by year

No proxy on file names a change to the peer group.

The comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year. Each company counts TSR from its own start year, so two values compare only when the start years match.